N-methyl-3-methoxy-2-methyl-4-pyridone | 60574-68-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-methyl-3-methoxy-2-methyl-4-pyridone
• 英文别名: 3-methoxy-1,2-dimethyl-4-pyridone；3-methoxy-1,2-dimethyl-1H-pyridin-4-one；3-Methoxy-1,2-dimethyl-1H-pyridin-4-on；3-Methoxy-1,2-dimethylpyridin-4(1H)-one；3-methoxy-1,2-dimethylpyridin-4-one
• CAS: 60574-68-7
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: RUHDPEYOMXHWPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-methyl-3-methoxy-2-methyl-4-pyridone 以 甲苯 为溶剂， 反应 100.0h， 以35%的产率得到3-(Hydroxymethyl)-1,2-dimethylpyridin-4-one
  参考文献：
  名称：

  Stiplosek, Z.; Sindler-Kulyk, M.; Jakopcic, K., Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 1707 - 1711

  摘要：

  DOI：
• 作为产物：
  描述：

  3-甲氧基-2-甲基-4H-吡喃-4-酮 、 甲胺 在 水 作用下， 生成 N-methyl-3-methoxy-2-methyl-4-pyridone
  参考文献：
  名称：

  STUDIES ON γ-PYRONES. II. SYNTHESIS OF 4-PIPERIDINOLS FROM PYRONES¹

  摘要：

  DOI：

  10.1021/jo01148a016

文献信息

• Solvent and substituent effects on the conversion of 4-methoxypyridines to N-methyl-4-pyridones
  作者：Xiao Yi、Jing Chen、Xiuling Xu、Yongmin Ma

  DOI：10.1080/00397911.2017.1290804

  日期：2017.5.3

  ABSTRACT In the reaction of 4-methoxypyridine derivatives with alkyl iodides in the presence or absence of solvent, not only the pyridinium ions but also the related 1-methylpyridones are produced. The presence of solvent favors the formation of the 1-methylpyridone. Electron withdrawing groups on the pyridine ring also favor this conversion. A possible mechanism is presented. GRAPHICAL ABSTRACT

  摘要 在有或无溶剂存在下，4-甲氧基吡啶衍生物与烷基碘反应，不仅生成吡啶鎓离子，而且生成相关的1-甲基吡啶酮。溶剂的存在有利于1-甲基吡啶酮的形成。吡啶环上的吸电子基团也有利于这种转化。提出了一种可能的机制。图形概要
• COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS
  申请人：Cellixbio Private Limited

  公开号：US20150148352A1

  公开（公告）日：2015-05-28

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of angina and cardiovascular conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic aneurysm, angina, atherosclerosis, cerebrovascular accident (stroke), cerebrovascular disease, congestive heart failure, coronary artery disease, myocardial infarction (heart attack), peripheral vascular disease, aortic dissection, aortic stenosis, arrhythmia (irregular heartbeat), atrial fibrillation, cardiomyopathy, chest pain, claudication, congenital heart disease.

  本发明涉及公式I化合物或其药学上可接受的盐，以及其多晶形、溶剂化合物、对映体、立体异构体和水合物。该药物组合物包括有效量的公式I化合物，并可制备用于口服、颊下、直肠、局部、经皮、经黏膜、静脉、肌肉注射、糖浆或注射的药物组合物，用于治疗心绞痛和心血管疾病的方法。这些组合物可用于治疗慢性动脉瘤、心绞痛、动脉粥样硬化、脑血管意外（中风）、脑血管疾病、充血性心力衰竭、冠状动脉疾病、心肌梗死（心脏病发作）、周围血管疾病、主动脉夹层、主动脉瓣狭窄、心律失常（心跳不规则）、心房颤动、心肌病、胸痛、跛行、先天性心脏病。
• STUDIES ON γ-PYRONES. II. SYNTHESIS OF 4-PIPERIDINOLS FROM PYRONES¹
  作者：KENNETH N. CAMPBELL、JOSEPH F. ACKERMAN、BARBARA K. CAMPBELL

  DOI：10.1021/jo01148a016

  日期：1950.3
• STIPLOSEK, Z.;SINDLER-KULYK, M.;JAKOPCIC, K.;MEIC, Z.;VIKIC-TOPIC, D., J. HETEROCYCL. CHEM., 36,(1989) N, C. 1707-1711
  作者：STIPLOSEK, Z.、SINDLER-KULYK, M.、JAKOPCIC, K.、MEIC, Z.、VIKIC-TOPIC, D.

  DOI：——

  日期：——
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE AND CHRONIC METABOLIC DISEASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES ET MÉTABOLIQUES CHRONIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014087323A2

  公开（公告）日：2014-06-12

  The invention relates to the compounds of formula I, formula II, formula III and formula IV or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III or formula IV and methods for the treatment of autoimmune and chronic metabolic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases, metabolic diseases, chronic kidney disease and autoimmune diseases.